InMed Pharmaceuticals Inc Asset Resilience Ratio
InMed Pharmaceuticals Inc asset resilience ratio. InMed Pharmaceuticals Inc (INM) has an Asset Resilience Ratio of 1.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See InMed Pharmaceuticals Inc (INM) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of InMed Pharmaceuticals Inc (2001–2026)
Asset resilience ratio of InMed Pharmaceuticals Inc from 2001 to 2026. This chart shows how InMed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read INM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down InMed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see InMed Pharmaceuticals Inc (INM) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $39.67 Million | 1.31% |
| Total Liquid Assets | $39.67 Million | 1.31% |
Asset Resilience Insights
- Limited Liquidity: InMed Pharmaceuticals Inc maintains only 1.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
InMed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare InMed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
InMed Pharmaceuticals Inc Asset Resilience Ratio by Year (2001–2026)
InMed Pharmaceuticals Inc asset resilience ratio by year from 2001 to 2026. The table below shows the annual Asset Resilience Ratio data for InMed Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-06-30 | 1.31% | $39.67 Million | $3.03 Billion | +1.10pp |
| 2025-06-30 | 0.21% | $43.56K | $21.23 Million | -0.15pp |
| 2022-06-30 | 0.35% | $57.69K | $16.46 Million | -0.12pp |
| 2021-06-30 | 0.48% | $57.46K | $12.10 Million | -0.07pp |
| 2020-06-30 | 0.54% | $42.38K | $7.80 Million | -25.56pp |
| 2019-06-30 | 26.10% | $3.93 Million | $15.07 Million | +17.75pp |
| 2018-06-30 | 8.35% | $1.78 Million | $21.34 Million | +5.59pp |
| 2003-06-30 | 2.75% | $32.04K | $1.16 Million | -45.03pp |
| 2002-06-30 | 47.78% | $651.24K | $1.36 Million | +1.80pp |
| 2001-06-30 | 45.98% | $2.15 Million | $4.67 Million | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more